Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

Recent & Breaking News (TSXV:VM)

Voyageur Pharmaceuticals Ltd. Announces Increase to Private Placement and First Closing

TheNewsWire December 31, 2020

Voyageur Files Further Updated NI 43-101 Report on the Frances Creek Barite Project

TheNewsWire December 18, 2020

Solving a Critical Supply Problem for North American Pharmaceuticals

Stockhouse Editorial December 16, 2020

Voyageur Pharmaceuticals Ltd. Announces up to $600,000 Private Placement

TheNewsWire December 9, 2020

Voyageur Pharmaceuticals Ltd. Announces Signing LOI for Contract Manufacturing of Barium Radiographic Contrast Media with Alberta Veterinarian Laboratories Ltd.

TheNewsWire November 30, 2020

Voyageur Pharmaceuticals Ltd. Announces Withdrawal of Corporate Presentation and Update on the Fullerene Project

TheNewsWire November 18, 2020

Voyageur Files Updated NI-43-101 Report on the Frances Creek Project & Completes SGS Canada Inc. Mine Site Visit for Advancement of PEA

TheNewsWire November 2, 2020

Voyageur to Collaborate with THINQ on Leading Pharma Development

Stockhouse Editorial July 28, 2020

Voyageur Signs Letter of Intent to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term Pharmaceutical Drug Development

TheNewsWire July 27, 2020

Generating a New Era in Carbon-Based, Anti Viral & Anti-Aging Drug Development

Dave Jackson May 21, 2020

Voyageur Secures Exclusive Rights To One Of The Worlds Rarest Pharmaceutical Minerals, Creating A New Era In Carbon Based Drug Development

GlobeNewswire May 11, 2020

Voyageur Announces Year-End Audited Financial Statements & MD&A

TheNewsWire April 3, 2020

Voyageur Announces the Postponement of Filing Annual Financial Statements and MD&A due to COVID-19 related delays. Reschedules for April 3, 2020

TheNewsWire March 27, 2020

Voyageur Restructures its ImagingX Joint Venture

GlobeNewswire March 20, 2020

InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' New "From the Earth to the Bottle" Fully-Integrated Iodine Business Strategy - Video Available on Investmentpitch.com

Newsfile February 27, 2020

Voyageur Pharmaceuticals Announces its "From The Earth To The Bottle" Iodine Contrast Strategy

GlobeNewswire February 26, 2020

Voyageur Announces New Chief Financial Officer, Issuance of Shares and Warrants to Extinguish Debt, and Issuance of Stock Options

TheNewsWire February 24, 2020

Voyageur Pharmaceuticals Implements Frances Creek Environmental Strategy for Bulk Sample and Future Quarry Production

GlobeNewswire February 18, 2020

One of the Purest Natural Barite Finds in the World

Dave Jackson February 5, 2020

InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' Confirmation that Frances Creek Barite Meets Pharma Grade Specifications - Video Available on Investmentpitch.com

Newsfile February 4, 2020